Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia

Dezima Pharma B.V. (head office: Netherlands, CEO: Rob de Ree, hereinafter, Dezima) is the licensee for TA-8995 (CETP inhibitor), a treatment agent for dyslipidemia discovered by Mitsubishi Tanabe Pharma. Dezima received an acquisition offer from Amgen, Inc. (head office: California, U.S., CEO: Robert A. Bradway, hereinafter, Amgen), and Amgen and Dezima announced an acquisition agreement on September 16 (PST).

Due to Amgen’s acquisition of Dezima, Mitsubishi Tanabe Pharma, Amgen, and Dezima have concluded patent, know-how transfer and future agreements for TA-8995.

In accordance with these agreements, Mitsubishi Tanabe Pharma will provide TA-8995 patents and rights to Amgen, worldwide, except for Japan and certain parts of Asia, where Mitsubishi Tanabe Pharma has retained the exclusive rights.

According to press releases by Amgen and Dezima, the acquisition will include a lump-sum payment of US $300 million and milestone payments in accordance with development and commercial progress, with a maximum total amount of US $1.25 billion. Low single-digit royalties will be paid on net product sales above a certain sales threshold. Mitsubishi Tanabe Pharma will receive from Dezima a portion from those payments over time.

TA-8995 is a CETP inhibitor that was originated by Mitsubishi Tanabe Pharma and licensed to Dezima in 2012. Dezima conducted the Phase 2b clinical trial and obtained the data which showed the strong LDL-C lowering effects of 45 to 48 percent compared to baseline in the dyslipidemia patients treated by once-daily TA-8995 as monotherapy or in combination with statins. The favorable results of the trial were reported in the authoritative U.K. medical journal "The Lancet".

Mitsubishi Tanabe Pharma plans to record the lump-sum payment in 2nd half of FY2015. The effect on Mitsubishi Tanabe Pharma’s results is currently being considered, and further information will be provided at a later date.

End